Efficacy of a tailored approach with nivolumab (N) and nivolumab plus ipilimumab (N plus I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC

被引：0
|
作者：
Grimm, M-O. [1 ]
Schostak, M. [2 ]
Gruen, C. B. [3 ]
Loidl, W. C. [4 ]
Pichler, M. [5 ]
Zimmermann, U. [6 ]
Schmitz-Draeger, B. J. [7 ]
Steiner, T. [8 ]
Roghmann, F. [9 ]
Niegisch, G. [10 ]
Schmitz, M. [11 ]
Baretton, G. [12 ]
Leucht, K. [1 ]
Schumacher, U. [13 ]
Foller, S. [14 ]
Zengerling, F. [15 ]
Meran, J. [16 ]
机构：
[1] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[2] Magdeburg Univ Hosp, Dept Urol, Magdeburg, Germany
[3] Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[4] Elisabethinen Hosp, Dept Urol, Linz, Austria
[5] Graz Univ Hosp, Dept Oncol, Graz, Austria
[6] Greifswald Univ Hosp, Dept Urol, Greifswald, Germany
[7] St Theresien Krankenhaus, Urol 24, Nurnberg, Germany
[8] Helios Hosp Erfurt, Dept Urol, Erfurt, Germany
[9] Univ Hosp Ruhr Univ Bochum, Marien Hosp Herne, Dept Urol, Herne, Germany
[10] Heinrich Heine Univ Dusseldorf, Dusseldorf Univ Hosp, Dept Urol, Dusseldorf, Germany
[11] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Immunol, Dresden, Germany
[12] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Pathol, Dresden, Germany
[13] Friedrich Schiller Univ Jena, Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[14] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[15] Ulm Univ Hosp, Dept Urol, Ulm, Germany
[16] Hosp Barmherzige Brueder, Dept Internal Med Hematol & Internal Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2372P
引用
收藏
页码：S1207 / S1208
页数：2
相关论文
共 50 条
  • [41] Efficacy of first-line (1L) nivolumab (N) plus ipilimumab (I) by tumor histologic subtype in patients ( pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
    Borghaei, H.
    Balli, D.
    Paz-Ares, L.
    Reck, M.
    Ramalingam, S. S.
    Brahmer, J. R.
    Ciuleanu, T-E.
    Pluzanski, A.
    Lee, J-S.
    Gainor, J.
    Schenker, M.
    Schoenfeld, A.
    Caro, R. Bernabe
    Ready, N.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Baxi, V.
    Geese, W.
    O'Byrne, K. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S64 - S65
  • [42] Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
    Albiges, Laurence
    Motzer, Robert J.
    Trevino, Sergio
    Kanesvaran, Ravindran
    Centkowski, Piotr
    Reimers, Melissa A.
    Sade, Juan Pablo
    Pouessel, Damien
    Biscaldi, Elisa
    Esteban, Emilio
    Arranz Arija, Jose Angel
    Tykodi, Scott S.
    Ma, Haijun
    Zhou, Lei
    Van Kooten Losio, Maximiliano A. G.
    Simmons, Andrew
    Rangwala, Fatima A.
    Braun, David A.
    Choueiri, Toni K.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [43] Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I plus N).
    Desai, Kunal
    Rybicki, Lisa A.
    Nizam, Amanda
    Wood, Laura S.
    Allman, Kimberly D.
    Martin, Allison
    Calabrese, Cassandra
    Gilligan, Timothy D.
    Gupta, Shilpa
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
    Escudier, B.
    Tannir, N. M.
    McDermott, D. F.
    Frontera, O. A.
    Melichar, B.
    Plimack, E. R.
    Barthelemy, P.
    George, S.
    Neiman, V.
    Porta, C.
    Choueiri, T. K.
    Powles, T.
    Donskov, F.
    Salman, P.
    Kollmannsberger, C. K.
    Rini, B.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Characterization of the benefit-risk profile of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced renal cell carcinoma (aRCC; CheckMate 214).
    Tannir, Nizar M.
    Hammers, Hans J.
    Amin, Asim
    Grimm, Marc-Oliver
    Rini, Brian I.
    Mekan, Sabeen
    McHenry, M. Brent
    Kollmannsberger, Christian K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
    Girardi, Daniel da Motta
    Niglio, Scot Anthony
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N plus CT) or nivolumab plus ipilimumab (N plus I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648
    Chau, I.
    Bridgewater, J. A.
    Wyrwicz, L. S.
    Greenwood, M.
    Blum, S. I.
    Moreno-Koehler, A.
    Martin, E.
    Taylor, F.
    Davis, C.
    Singh, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S162 - S162
  • [48] Ipilimumab and nivolumab (I plus N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.
    Allison, Jennifer
    Griffiths, Richard
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [49] Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Schenker, Michael
    Bordenave, Stephanie
    Cobo, Manuel
    Juan-Vidal, Oscar
    Reinmuth, Niels
    Richardet, Eduardo
    Felip, Enriqueta
    Menezes, Juliana
    Cheng, Ying
    Mizutani, Hideaki
    Carbone, David Paul
    Lu, Shun
    John, Tom
    Aoyama, Takekazu
    Mahmood, Javed
    Hu, Nan
    Eccles, Laura
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Nivolumab plus ipilimumab (N plus I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Chan, John K.
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Cannon, Timothy Lewis
    Ahn, Eugene R.
    Swiecicki, Paul
    Hobbs, Evthokia
    Nazemzadeh, Reza
    Bell, Maria C.
    Hosein, Peter Joel
    Meric-Bernstam, Funda
    Hinshaw, Dominique C.
    Gregory, Abby
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345